Riociguat for the treatment of pulmonary hypertension in patients with end stage renal disease

Pulmonary hypertension is a progressive condition with significant associated morbidity and mortality. The prevalence of pulmonary hypertension (PH) in patients with end stage renal disease (ESRD) has been estimated to be as high as 80  %, yet little data is available on the management of PH in this particular population [1]. While the etiology of pulmonary hypertension is often multifactorial, PH due to chronic renal failure is classified as World Health Organization (WHO) group 5 [2]. Currently, approved therapies exist primar ily for the treatment of Group 1 (pulmonary arterial hypertension) and Group 4 (chronic thromboembolic) pulmonary hypertension, with recent data also showing a benefit from inhaled trepostinil for patients with Group 3 PH due to ILD [3].

Source: Respiratory Medicine - November 5, 2023 Category: Respiratory Medicine Authors: Peter Cangialosi, Ewelina Wojtaszek, Alaa Omar, Radha Gopalan, Dileyni Abel, Elizabeth Tinuoye, Johanna P. Contreras, Barry A. Love, Maria Giovanna Trivieri Tags: Short communication Source Type: research